Article info

Download PDFPDF

Correspondence on ‘Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?’
Free

Authors

  1. Correspondence to Dr Socrates Angelides, Nuclear Medicine, The University of Sydney Faculty of Medicine and Health, Sydney, New South Wales, Australia; Socrates.Angelides{at}health.nsw.gov.au
View Full Text

Citation

Angelides S, Manolios N
Correspondence on ‘Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, low-grade systemic inflammation?’

Publication history

  • Received December 12, 2020
  • Accepted December 15, 2020
  • First published January 27, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.